Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

Talha Badar, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Jorge E. Cortes, Naveen Pemmaraju, Sherry R. Pierce, Kate J. Newberry, Naval Daver, Srdan Verstovsek

Research output: Contribution to journal › Article › peer-review

67 Scopus citations

Fingerprint

Dive into the research topics of 'Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase'. Together they form a unique fingerprint.

Medicine & Life Sciences